Chemestmed Partners with FutureNeuro Research Ireland Centre and UCD to Explore METTL3/14 Activators for Epilepsy
Chemestmed is proud to announce a new research collaboration with FutureNeuro, the Research Ireland Centre for Translational Brain Science, and the research team led by Dr. Gary Brennan at University College Dublin.
Together, we will investigate the anticonvulsant and anti-epileptogenic potential of Chemestmed’s METTL3/14 activators; a novel class of small-molecule compounds that enhance RNA methylation.
This partnership marks an important step in expanding the therapeutic potential of our first-in-class RNA-modifying compounds into epilepsy research.
Through this collaboration, Chemestmed brings its expertise in drug discovery and RNA epigenetics, while our academic partners contribute deep knowledge in neuroscience, epilepsy models, and translational research.
We’re excited to work together to explore innovative ways to address unmet needs in epilepsy treatment.
